233 related articles for article (PubMed ID: 28497796)
1. Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.
Vazquez-Lombardi R; Loetsch C; Zinkl D; Jackson J; Schofield P; Deenick EK; King C; Phan TG; Webster KE; Sprent J; Christ D
Nat Commun; 2017 May; 8():15373. PubMed ID: 28497796
[TBL] [Abstract][Full Text] [Related]
2. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
3. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
Arenas-Ramirez N; Zou C; Popp S; Zingg D; Brannetti B; Wirth E; Calzascia T; Kovarik J; Sommer L; Zenke G; Woytschak J; Regnier CH; Katopodis A; Boyman O
Sci Transl Med; 2016 Nov; 8(367):367ra166. PubMed ID: 27903862
[TBL] [Abstract][Full Text] [Related]
4. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD25 monoclonal antibody Fc variants differentially impact regulatory T cells and immune homeostasis.
Huss DJ; Pellerin AF; Collette BP; Kannan AK; Peng L; Datta A; Wipke BT; Fontenot JD
Immunology; 2016 Jul; 148(3):276-86. PubMed ID: 27012310
[TBL] [Abstract][Full Text] [Related]
6. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
Votavova P; Tomala J; Kovar M
Immunol Lett; 2014; 159(1-2):1-10. PubMed ID: 24512738
[TBL] [Abstract][Full Text] [Related]
7. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
[TBL] [Abstract][Full Text] [Related]
8. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
9. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.
Teng MW; Swann JB; von Scheidt B; Sharkey J; Zerafa N; McLaughlin N; Yamaguchi T; Sakaguchi S; Darcy PK; Smyth MJ
Cancer Res; 2010 Apr; 70(7):2665-74. PubMed ID: 20332236
[TBL] [Abstract][Full Text] [Related]
10. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.
Kim PS; Kwilas AR; Xu W; Alter S; Jeng EK; Wong HC; Schlom J; Hodge JW
Oncotarget; 2016 Mar; 7(13):16130-45. PubMed ID: 26910920
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.
Hallett WHD; Ames E; Álvarez M; Barao I; Taylor PA; Blazar BR; Murphy WJ
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1088-1099. PubMed ID: 18804038
[TBL] [Abstract][Full Text] [Related]
12. [Influence of regulatory T cells on the functioning of natural killer cells during cancer immunotherapy].
Chikileva IO; Shubina IZh; Kiselevskiĭ MV
Vestn Ross Akad Med Nauk; 2012; (4):60-4. PubMed ID: 22834330
[TBL] [Abstract][Full Text] [Related]
13. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4
Yan JJ; Lee JG; Jang JY; Koo TY; Ahn C; Yang J
Kidney Int; 2017 Mar; 91(3):603-615. PubMed ID: 27914701
[TBL] [Abstract][Full Text] [Related]
14. Selective stimulation of T cell subsets with antibody-cytokine immune complexes.
Boyman O; Kovar M; Rubinstein MP; Surh CD; Sprent J
Science; 2006 Mar; 311(5769):1924-7. PubMed ID: 16484453
[TBL] [Abstract][Full Text] [Related]
15. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.
Dinh TN; Kyaw TS; Kanellakis P; To K; Tipping P; Toh BH; Bobik A; Agrotis A
Circulation; 2012 Sep; 126(10):1256-66. PubMed ID: 22851544
[TBL] [Abstract][Full Text] [Related]
16. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
18. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.
Levin AM; Bates DL; Ring AM; Krieg C; Lin JT; Su L; Moraga I; Raeber ME; Bowman GR; Novick P; Pande VS; Fathman CG; Boyman O; Garcia KC
Nature; 2012 Mar; 484(7395):529-33. PubMed ID: 22446627
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.
Hu Q; Ye X; Qu X; Cui D; Zhang L; Xu Z; Wan H; Zhang L; Tao W
Sci Rep; 2018 May; 8(1):7675. PubMed ID: 29769573
[TBL] [Abstract][Full Text] [Related]
20. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Arce Vargas F; Furness AJS; Solomon I; Joshi K; Mekkaoui L; Lesko MH; Miranda Rota E; Dahan R; Georgiou A; Sledzinska A; Ben Aissa A; Franz D; Werner Sunderland M; Wong YNS; Henry JY; O'Brien T; Nicol D; Challacombe B; Beers SA; ; ; ; Turajlic S; Gore M; Larkin J; Swanton C; Chester KA; Pule M; Ravetch JV; Marafioti T; Peggs KS; Quezada SA
Immunity; 2017 Apr; 46(4):577-586. PubMed ID: 28410988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
